Provention Bio, Inc.
PRVBDelisted Apr 27, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001695357
Provention Bio, Inc. was delisted on Apr 27, 2023; its insiders filed their last Form 4 on Apr 28, 2023; 183 institutions reported holding it in 13F filings for Q1 2023, worth $1.47B in total; Fairfax Financial was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Provention Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Provention Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 10% Owner | 0 | Apr 28, 2023 | 0 |
| Sessa Capital (Master), L.P. | 10% Owner | 0 | Apr 28, 2023 | 0 |
| Sessa Capital GP, LLC | 10% Owner | 0 | Apr 28, 2023 | 0 |
| Sessa Capital IM GP, LLC | 10% Owner | 0 | Apr 28, 2023 | 0 |
| Petry John | 10% Owner | 0 | Apr 28, 2023 | 0 |
| Catlin Avery W | Director | 0Indirect | Apr 27, 2023 | 0 |
| Wysenski Nancy | Director | – | Apr 27, 2023 | 0 |
| Ramos Eleanor | Chief Medical Officer | 0 | Apr 27, 2023 | 0 |
| Palmer Ashleigh | Director and CEO | 0 | Apr 27, 2023 | 0 |
| Vogel Justin | Chief Accounting Officer | – | Apr 27, 2023 | 0 |
| Jain Rita | Director | – | Apr 27, 2023 | 0 |
| Leon Francisco | Chief Scientific Officer | 0Indirect | Apr 27, 2023 | 0 |
| Osorio Benedict | Chief Quality Officer | – | Apr 27, 2023 | 0 |
| Jenkins John Kenneth | Director | – | Apr 27, 2023 | 0 |
| Pisano Wayne | Director | 0 | Apr 27, 2023 | 0 |
| Hoitt Jason | Chief Commercial Officer | 0 | Apr 27, 2023 | 0 |
| King-Jones Heidy | Chief Legal Officer | – | Apr 27, 2023 | 0 |
| Chauche Thierry | Chief Financial Officer | – | Apr 27, 2023 | 0 |
| Yi Miyoko Christina | Chief Operations Officer | – | Apr 27, 2023 | 0 |
| O'Brien Sarah | Chief People Officer | – | Jan 11, 2023 | 0 |
| Bluestone Jeffrey | Director | – | May 18, 2022 | 0 |
| Doherty Sean M | Director | – | May 18, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 18, 2023 (view filing)8:57 PM ET | Apr 14 | 4 days | Sessa Capital IM, L.P. and 4 others10% Owner | SSale | −2.19M | $24.32 | −$53.3M | −12.3%15.6M after | |
| Feb 14, 2023 (view filing) | Feb 10-13 | 4 days | Leon FranciscoChief Scientific Officer | SSale | −76.0K | $10.09 | −$766.4K | −4.6%1.57M after | 2 lots |
| Feb 14, 2023 (view filing) | Feb 10 | 4 days | Hoitt JasonChief Commercial Officer | SSale | −4.50K | $10.00 | −$45.0K | −100.0%0 after | |
| Feb 14, 2023 (view filing) | Feb 10-13 | 4 days | Palmer AshleighDirector and CEO | SSale | −75.8K | $10.09 | −$764.9K | −2.9%2.57M after | 2 lots |
| Jan 20, 2023 (view filing)4:10 PM ET | Jan 18 | 2 days | Sessa Capital IM, L.P. and 4 others10% Owner | SSale | −3.00M | $9.40 | −$28.2M | −20.2%11.9M after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Palmer AshleighDirector and CEO | SSale | −24.2K | $10.27 | −$248.2K | −0.9%2.57M after | |
| Jan 20, 2023 (view filing) | Jan 18 | 2 days | Leon FranciscoChief Scientific Officer | SSale | −24.0K | $10.27 | −$246.6K | −1.5%1.57M after | |
| Dec 30, 2022 (view filing) | Dec 29 | 1 day | Leon FranciscoChief Scientific Officer | SSale | −187.0K | $10.26 | −$1.92M | −10.6%1.57M after | |
| Dec 29, 2022 (view filing) | Dec 27 | 2 days | Leon FranciscoChief Scientific Officer | SSale | −10.7K | $10.00 | −$106.7K | −0.7%1.57M after | |
| Dec 27, 2022 (view filing) | Dec 22-23 | 5 days | Leon FranciscoChief Scientific Officer | SSale | −1.94K | $10.00 | −$19.4K | −0.1%1.57M after | 2 lots |
| Dec 6, 2021 (view filing) | Dec 3 | 3 days | Ramos EleanorChief Medical Officer | PPurchase | +5.20K | $6.49 | +$33.8K | +8.0%70.0K after | |
| Dec 1, 2021 (view filing) | Nov 30 | 1 day | Palmer AshleighDirector and CEO | PPurchase | +3.75K | $6.66 | +$25.0K | +0.1%2.57M after | |
| Nov 29, 2021 (view filing) | Nov 24 | 5 days | Leon FranciscoChief Scientific Officer | PPurchase | +5.55K | $7.24 | +$40.2K | +0.2%2.57M after |